期刊
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
卷 12, 期 1, 页码 1-4出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2016.1112739
关键词
psoriasis; brodalumab; ixekizumab; secukinumab; interleukin-17
类别
Interleukin (IL) 17-A appears to be integral to the pathogenesis of chronic plaque psoriasis. Recent clinical trials have shown that blockade of this cytokine with the biologic therapiessecukinumab, ixekizumab and brodalumabhave led to unprecedented treatment efficacy for psoriasis. In addition, their dual efficacy towards psoriatic arthritis increases their potential clinical utility and they promise to be an important treatment option for patients who have tumour necrosis factor inhibitor resistant disease. Here, we present the evidence for the high treatment efficacy of the IL-17A inhibitors but also discuss some potential questions and areas of research needed, including the lack of evidence behind the drug survival, immunogenicity and safety profile.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据